Physician profile
Robert Michael Busic
NPI 1447826011
$1,035.20
in general payments reported to CMS, 2019-2025
15 companies · $798 in 2025
The $798 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $21.76 · 2023: $29.40 · 2024: $186 · 2025: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,013.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $240.72 | 2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $159.12 | 2025 | |
| Abbvie INC. | $140.53 | 2024-2025 | |
| Exact Sciences Corporation | $115.45 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amgen INC. | $114.14 | 2025 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $43.37 | 2025 | Farxiga |
| Shield Therapeutics INC | $40.95 | 2024-2025 | |
| Lucid Diagnostics INC. | $35.42 | 2025 | |
| Boston Scientific Corporation | $29.40 | 2023 | Watchman Access System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.26 | 2024 | Xifaxan |
| Global Blood Therapeutics, INC. | $21.76 | 2022 | |
| Esperion Therapeutics, INC. | $19.83 | 2024 | Nexletol |
| Si-Bone, INC. | $19.67 | 2025 | |
| Lilly USA, LLC | $16.06 | 2024 | Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $15.52 | 2025 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Busic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.